The global surgical suction instruments market is projected to reach 503 million in 2029 from USD 375 million in 2024, at a CAGR of 6.1% between 2024 and 2029. The rising technological advancemnets and increasing geriatric population is driving the growth of the market. As the global population ages, the number of chronic diseases is increasing which is expected to drive the market growth.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=129636225
Elderly patients often experience age-related decline in appetite or swallowing difficulties, making enteral feeding a vital support system.
Based on type, the surgical suction instruments market is segmented into retractors, yankauer suction tube, poole suction tube, frazier suction tip, others. The yankauer suction tube accounts for the largest share in the surgical suction instruments market, the bulbous tip design and wide opening allow for efficient suction of blood, fluids, and debris from the surgical field. This improves visibility and reduces the risk of obscuring critical structures. which is expected to drive the segment growth.
Based on application, the surgical suction instruments market is segmented into general surgery, neurosurgery, orthopedic surgery, cardiovascular surgery, dental surgery. The general surgery accounts for the largest share in the surgical suction instruments market, Surgical suction instruments play a vital role in various aspects of general surgery, contributing to a clean and efficient operative environment. Suction removes blood, fluids, and debris from the surgical site, allowing the surgeon a clear view of the underlying anatomy. This is crucial for precise dissection, minimizing the risk of unintended injury to vital structures which is expected to drive the market growth.
In 2023, North America accounted for the largest share of the surgical suction instruments market, followed by Europe and Asia Pacific. The United States and Canada have well-equipped hospitals and a strong focus on advanced medical care, which supports the adoption of surgical suction instruments, also compared to established markets like North America and Europe, the Asia Pacific region often offers lower labor costs, making it an attractive option for companies seeking to optimize manufacturing expenses.
The major players in the surgical suction instruments market include include The prominent players in the medical device contract manufacturing market include include Olympus (Japan), Cardinal Health, Inc. (US), Stryker Corporation (US), Medtronic (Ireland), B. Braun Melsungen AG (Germany), CONMED Corporation (US), BD (US), Steris Plc (Ireland), Teleflex Incorporated (US), Carl Zeiss Meditech AG (Germany), Integra Lifesciences Holdings Corporation (US), KARL STORZ SE & CO. KG (Germany), Indosurgicals Private Limited (India), Applied Medical Technology, Inc. (US), Amsino International, Inc.(US), Surtex Instruments Limited (UK), Bionix LLC.(US), Vactechindia.Com (India), Applied Medical Resources Corporation (US), DTR Medical Ltd (UK), Sklar Surgical Instruments (US), PAJUNK (Germany), Hangzhou Kangji Medical Instrument Co.,Ltd.(China), Romsons (India), Narang Medical Limited.(India).
Recent Developments of the Surgical Suction Instruments Industry:
In January 2024, Olympus Corporation acquired the Taewoong Medical Co., Ltd., a Korea-based manufacturer of medical devices. This acquisition helps Olympus to strengthen its GI Endo Therapy product portfolio capabilities, contribute to improving patient outcomes through comprehensive solutions, and elevate the standard of care.
In May 2023, Stryker acquired the Cerus Endovascular Ltd. (UK), a medical device company engaged in the design and development of neurointerventional devices. Cerus Endovascular’s marked products, helped to expand Stryker’s current portfolio of aneurysm treatment solutions.
In September 2022, Cardinal Health, Inc. (US) announced the partnership with Kinaxis (Canada) to enhance the Kinaxis RapidResponse Platform used for supply chain agility and medical product visibility.
In July 2022, Medtronic and the American Society for Gastrointestinal Endoscopy expanded the Health Equity Assistance Program for colon cancer screening with support from Amazon Web Services. Completed first installation of donated GI Genius intelligent endoscopy modules.
The clinical communication & collaboration market is projected to reach USD 4.8 billion by 2029 from USD 2.6 billion in 2024, at a CAGR of 13.2% during the forecast period. The market growth is driven by the rising demand for telehealth, focus on care coordination and continuity, cost reduction and operational efficiency, and patient-centric care models over the forecast period.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=118830286
Based on application, the clinical communication & collaboration market is segmented into lab & radiology communication, nurse communication, patient communication & emergency alerts, physician communication. The physician communication segment holds the largest market share in the clinical communication & collaboration market because of its indispensable role in patient care, complex decision-making processes, emphasis on patient safety, interdisciplinary collaboration, mobility requirements, regulatory compliance needs, and evolving healthcare landscape.
Based on end user, the clinical communication & collaboration market is segmented into hospitals & clinics, ambulatory surgical centers, long-term care facilities, nursing centers and others. The hospitals & clinics dominated the segment in 2023. The growth of this segment is attributed to healthcare facilities operating within complex care environments, necessitating seamless communication among diverse stakeholders, including physicians, nurses, specialists, and support staff. Also, the sheer volume of patients treated in hospitals and large clinics amplifies the need for efficient communication and collaboration tools to manage workflows effectively.
The clinical communication & collaboration market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America holds the largest share of the clinical communication & collaboration market in 2023. This is attributed to highly developed healthcare infrastructure, with advanced hospitals, clinics, and healthcare systems that prioritize the adoption of cutting-edge technologies. This environment fosters a fertile ground for the implementation of clinical communication & collaboration solutions, driving market growth. Also, North America is home to a large number of leading technology companies specializing in healthcare IT and communication solutions. These companies innovate continuously to address the evolving needs of healthcare providers, offering a wide array of sophisticated communication platforms tailored for clinical settings. Furthermore, regulatory requirements in North America, such as the Health Insurance Portability and Accountability Act (HIPAA), mandate stringent standards for patient privacy and data security. As a result, healthcare organizations in the region prioritize investing in secure communication solutions that comply with these regulations, further driving market growth. Additionally, the region’s cultural and linguistic diversity necessitates flexible communication platforms capable of accommodating various languages and communication preferences, further fueling demand for advanced solutions. Moreover, North America has a robust telehealth infrastructure, which gained significant traction, especially during the COVID-19 pandemic, accelerating the adoption of telehealth-enabled communication platforms.
The Mental Health Screening market is projected to reach USD 1.8 billion by 2029 from USD 0.9 billion in 2023, at a CAGR 12.2% during the forecast period 2023-2029. The growth in this market is fuelled by the technological advancements, and the increasing focus on remote monitoring. Furthermore, the integration with wearable technologies and the rise of social media and its impact on the adoption of mental health screening tools, is anticipated to offer lucrative growth opportunities for market players in Mental Health Screening throughout the forecast period 2024-2029.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198516770
Based on application, the Mental Health Screening market is segmented into physiological, psychiatric, behavioural and cognitive disorders. Physiological disorders are further segmented into depression, anxiety, post-traumatic stress disorder (PTSD), bipolar disorder, eating disorder, substance abuse, and other physiological disorders. Among these sub-segments, substance abuse accounted for the largest share of the Mental Health Screening market in 2023 attributing to the global increase in substance abuse cases, fueled by factors such as stress, trauma, and societal pressures. Growing recognition of the interconnection between mental health and substance abuse play a pivotal role in addressing these challenges by encouraging healthcare providers to adopt integrated screening protocols.
Based on technology, the Mental Health Screening market is segmented into self-screening mHealth apps, telehealth & virtual care solutions, continuous monitoring wearable devices, AI-based screening tools, and remote mental health platforms. In 2022, the continuous monitoring wearable devices segment accounted for the largest share attributing to the advancements in wearable sensor technologies and the rising demand for real-time data insights.
Based on age group, the Mental Health Screening market is segmented into children & adolescents (age 0–18 years), adults (age 19–64 years), and seniors (age 65 and above). The adults (age 19-64 years) segment accounted for the largest share of the Mental Health Screening market. The rising workloads, economic pressures, and competitive environments contributing to stress and anxiety amplifies the demand for increasing mental health screening solutions among this age group.
The Mental Health Screening market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In 2022, Asia Pacific was the fastest growing segment in Mental Health Screening market attributed to the growing incidence of mental disorders, rising government initiatives for increasing awareness about mental disorders. Moreover, there is a heightened demand for the improved accessibility of mental health services due to increasing patient burden in this region.
Prominent players in Mental health screening market include Proem Behavioral Health (US), SonderMind Inc. (US), Riverside Community Care (US), Headspace Health (US), Quartet Health, Inc. (US), Canary Speech, Inc. (US), Sonde Health, Inc. (US), Koninklijke Philips N.V. (Netherlands), Alphabet Inc. (Fitbit) (US), ResMed (US), Apple Inc. (US), Wellin5 USA Inc. (Canada), Clarigent Health (US), Woebot Labs Inc. (US), Aiberry (US), Cognitive Health Solutions, LLC (US), Adaptive Testing Technologies (US), Thymia Limited (UK), Modern Life, Inc. (US), MoodFit (US), MoodTools (US), Kintsugi Mindful Wellness, Inc. (US), Ellipsis Health Inc. (US), FuturesTHRIVE (US), and CogniABle (India).
Recent Development of Mental Health Screening Industry:
In November 2023, SonderMind (US) acquired Total Brain (US) to expand its reach, offering individualized mental wellness, supporting therapists with enhanced care techniques, providing population mental health tools for enterprises, and delivering comprehensive solutions to health plans.
In October 2023, Ellipsis Health, Inc. (US) partnered with Augmedix (US) to introduce automated mental health screenings during patient visits.
In December 2021, Quartet Health, Inc. (US) successfully acquired InnovaTel Telepsychiatry (US), turning its vision of rapidly delivering high-quality mental healthcare for everyone into a reality.
The tissue engineering market is expected to reach USD 8.9 billion by 2028 from an estimated USD 4.4 billion in 2023, at a CAGR of 15.3% during the forecast period. The growth is attributed to numerous factors including increasing incidences of road accidents, rising demand for regenerative medicines for the treatment of chronic diseases, and growing technological advancements in the biopharmaceutical sector. In addition, increasing research activities in the field of tissue engineering is promoting the growth of the tissue engineering market.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34135173
3D bioprinting is an innovative technology in tissue engineering, that enables the precise fabrication of intricate tissue structures, vital for regenerative medicine and drug testing. Its development is primarily propelled by continual technological advancements, including improved bio inks and printing techniques, coupled with the critical need to address organ shortages and revolutionize medical treatments. Material innovation also plays a pivotal role, in fostering the creation of biocompatible substances essential for enhancing the viability and functionality of bio-printed tissues. Additionally, collaborative research efforts among multidisciplinary fields drive progress, promising transformative solutions in healthcare.
Based on product type, the tissue engineering market has been segmented into scaffolds, tissue grafts, and other products. In 2022, scaffolds accounted for the largest market share. Scaffold-driven tissue engineering hinges on biocompatibility, mechanical robustness, and optimal pore structure for cell infiltration and nutrient exchange. Integration of bioactive cues and vascular-like properties also fuels advancements, crucial for crafting functional and viable engineered tissues. These driving factors collectively shape scaffold design, influencing their efficacy in tissue engineering applications.
Based on material, the global tissue engineering market is segmented into synthetic materials and biologically derived materials. Synthetic material accounted for major market share of the tissue engineering market in 2022. The large share of this segment can be attributed to the cost effectiveness of the synthetic products as compared to the biologically derived products. In addition, increasing demand for advanced and cost-effective tissue engineering solutions is propelling the growth of the synthetic material segment in the tissue engineering market.
Based on application, the tissue engineering market is segmented into orthopedics & musculoskeletal disorders, dermatology & wound care, dental disorders, cardiovascular diseases, and others. In 2022, orthopedics & musculoskeletal disorders accounted for the largest share of the global tissue engineering market. The large share of the segment can primarily be attributed to rising demand for high quality tissue engineering products for the repair and reconstruction of damaged tissues or organs. Additionally, increasing incidences of road accidents are promoting the adoption of tissue engineering products for tissue reconstruction.
Based on end users, the tissue engineering market has been segmented into hospitals, specialty centers and clinics, and ambulatory surgical centers. Hospitals accounted for the largest market share of the tissue engineering market. The large share of the segment can primarily be attributed to the increasing demand for advanced regeneration solutions for the reconstruction and regeneration of tissues. Additionally, the increasing rate of chronic and degenerative diseases is driving the demand for hospitals.
The key regional markets for the global tissue engineering market are Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America accounted for the largest share of the market. The large share of this region can be attributed to the growing technological developments in the healthcare sector and rising research activities for the advancements of the tissue engineering field. However, most of the growth in the market is expected from emerging countries across Asia Pacific. During the forecast period, the Asia Pacific is expected to grow with the fastest CAGR due to the increasing adoption of innovative technologies for the treatment of chronic and degenerative diseases.
Key players in the global tissue engineering market include Organogenesis (US), AbbVie Inc. (US), Baxter (US), BD (US), B. Braun (Germany), TEIJIN Limited (Japan), Institut Straumann AG (Switzerland), Integra Lifesciences (US), Johnson & Johnson Services, Inc. (US), Medtronic (Ireland), NuVasive, Inc. (US), Stryker (US), Terumo Corporation (Japan), W. L. Gore & Associates Inc. (US), Zimmer Biomet (US), Smith & Nephew plc (UK), MIMEDX Group, Inc. (US), BioTissue (US), CollPlant Biotechnologies Ltd. (Israel), Sumitomo Pharma Co., Ltd. (Japan), Matricel GmbH (Germany), Mallinckrodt (US), Regrow Biosciences Pvt Ltd (India), Vericel Corporation (US), Tecnoss S.R.L. (Italy), Tegoscience (South Korea), and Tissue Regenix (UK).
The base editing market is projected to reach USD 549 million by 2028 from an estimated USD 270 million in 2023, at a CAGR of 15.2% during the forecast period. Factors like the rising prevalence of genetic diseases, coupled with advancements in molecular biology and biotechnology, has spurred research and development efforts in base editing technologies. Additionally, the growing investment in gene therapy and the biopharmaceutical sector further accelerates the expansion of the base editing market.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=21238371
Based on product & service, the base editing market is segmented into products and services. The product segment is further categorized as platform, kits & reagents, plasmids, and base editing libraries. The service segment is further categorized as gRNA design/synthesis, cell line engineering, and other services. Platform accounted for the largest share of the global base editing market in 2022. The large share of this segment can primarily be attributed to the increasing demand for base editing in molecular studies and the discovery of new therapies.
Based on type, the global base editing market is segmented into DNA base editing, and RNA base editing. In 2022, DNA-targeted base editing accounted for the largest share of the base editing market. The large share of this segment can be attributed to the factor that DNA base editing leads to changes in the genomic DNA sequence, making the edits permanent. This can be advantageous when long-lasting or heritable modifications are desired, as the edited DNA is passed on to subsequent generations of cells.
Based on targeted base, the base editing market has been segmented into cytosine base editing, and adenine base editing. In 2022, cytosine base editing accounted for the largest market share because cytosine base editors (CBEs) are designed to convert a C-G base pair to a T-A base pair. This type of transition is more common in naturally occurring DNA sequences, making cytosine editing suitable for introducing changes that are biologically relevant.
Based on application, the base editing market has been segmented into drug discovery & development, agriculture, and veterinary. In 2022, the drug discovery & development segment accounted for the largest share of the base editing market. The large share of this segment can be attributed to the potential of base editing for developing novel therapeutic interventions by correcting disease-causing mutations at the DNA or RNA level. This is especially relevant for genetic disorders where a single nucleotide mutation is responsible for the disease.
Based on end users, the base editing market has been segmented into pharmaceutical & biotechnology companies, academic research institutes, and contract research organizations. In 2022, the pharmaceutical & biotechnology segment accounted for the largest share of the base editing market. The large share of this segment is due to the potential of base editing in drug development; companies in the pharmaceutical and biotechnology sectors are investing in this technology to secure intellectual property, technology, and product rights and gain a competitive advantage in the rapidly evolving field of genome editing. For instance, in October 2023, Beam Therapeutics announced an agreement with Eli Lilly and Company (Lilly) to acquire certain rights under Beam’s collaboration and license agreement with Verve Therapeutics, Inc., including Beam’s opt-in rights to co-develop and co-commercialize Verve’s base editing programs for cardiovascular disease.
The key regional markets for the global base editing market are North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America accounted for the largest share of the market. The large share of this region is due to the robust biotechnology and pharmaceutical industry, with numerous companies dedicated to drug discovery, development, and therapeutic applications. These companies actively invest in and adopt emerging technologies like base editing for advancing their research and product pipelines. However, most of the growth in the market is expected from emerging countries across Asia Pacific. During the forecast period, the Asia Pacific is expected to be the fastest-growing regional market. Factors such as the emergence of CROs for outsourcing drug discovery-related research projects and increasing pharmaceutical drug pipelines are driving growth in these markets.
Key players in the global Base editing market include Danaher Corporation (US), Merck KGaA (Germany), Revvity (US), Maravai LifeSciences (US), GenScript (China), Beam Therapeutics (US), Intellia Therapeutics, Inc. (US), Cellectis (France), ElevateBio (US), Creative Biogene (US), Bio Palette Co., Ltd (Japan), Addgene (US), Synthego (US), EdiGene, Inc. (China), Shape TX (US), Pairwise (US), ProQR Therapeutics (Netherlands), QI-Biodesign (China), KromaTiD, Inc. (US), and GenKOre. (South Korea).
The global transdermal patches market is projected to reach 8.0 USD Billion by 2029 from USD 6.2 Billion in 2023, at a CAGR of 4.5% from 2023 to 2029. The global market for transdermal patches is expanding as a result of a number of causes, including the rising incidence of chronic illnesses, the expanding use of analgesic patches, technological developments in transdermal patches, and the shift from traditional injections to transdermal patches. However, over the anticipated period, obstacles such as medication failure, transdermal drug delivery system recalls, and the escalating expense of healthcare facilities would probably limit market expansion to some extent.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=190809043
A transdermal patch is a medicated adhesive patch that delivers medication through the skin into the bloodstream. Transdermal patches are a convenient and effective way to deliver medication, as they can provide a steady and controlled release of medication over time.
On the basis of patch type, the transdermal patches market is segmented into Drug-In-Adhesive, Matrix Patches, Reservoir Membrane Patches, Microneedle Patches, Iontophoresis Patches, and Vapour Patches. In 2022, the Drug-In-Adhesive segment accounted for the largest share of the transdermal patches market. The drug-in-adhesive patch market is expected to continue to grow in the coming years. This is due to the increasing prevalence of chronic diseases, the growing popularity of non-invasive drug delivery methods, and the development of new and innovative drug-in-adhesive patches.
Based on adhesive type, the transdermal patches market is segmented into Acrylic Adhesives, Silicone Adhesives, Hydrogel Adhesives and Other Adhesives. In 2022, the Acrylic Adhesives segment accounted for the largest share of the transdermal patches market. The transdermal patch market is dominated by acrylic adhesive patches because of its many advantages over other kinds of adhesives. Acrylic adhesives possess strength, biocompatibility, permeability, flexibility, resistance to water, and affordability. These characteristics make them ideal for use in transdermal patches, where they may firmly stick to the skin and efficiently provide medication over an extended period of time.
Based on Application, the transdermal patches market is segmented into Pain Management, Smoking Cessation, Hormone Replacement Therapy, Cardiovascular Disorder, Central Nervous System Disorder and Others. The pain management patch claims the largest segment in the transdermal patch market due to its efficacy, convenience, and patient-friendly application. These patches provide a controlled release of pain-relieving medications directly through the skin into the bloodstream, offering a consistent and prolonged effect. The ease of use and non-invasive nature of transdermal patches make them particularly appealing for individuals seeking a discreet and hassle-free method of pain management.
Based on End Users, the transdermal patches market is segmented into Homecare Settings and Hospitals And Clinics. The Homecare Settings segment is estimated to grow at the highest CAGR during the forecast period. Home care settings eliminate the need for patients to travel to healthcare facilities, thus saving time and money. Owing to this convenience and better affordability, an increasing number of patients are opting for home-based treatments. Also, for patients requiring long-term therapy, inpatient care is not only extremely expensive but also prevents patients from resuming a normal lifestyle and work activities.
Geographically, North America is the largest regional market for transdermal patches market in 2022, followed by Europe. Due to a number of reasons that together account for a considerable portion of its market share, North America leads the largest section of the transdermal patch market. The region’s strong pharmaceutical regulatory framework, high incidence of chronic illnesses, and sophisticated healthcare infrastructure all contribute significantly to the transdermal patch’s extensive use. The need for these patches to treat chronic ailments including pain, hormone imbalances, and cardiovascular diseases has grown as a result of the aging population and greater awareness of non-invasive medication delivery techniques.
The prominent players in the global transdermal patches market are Nitto Denko Corporation (Japan), Hisamatsu Pharmaceuticals Co. Ltd. (Japan), Novartis AG (Switzerland), USB S.A. (Belgium), Boehringer Ingelheim International GmbH (Germany), Johnson & Johnson (U.S.), Viatris Inc. (U.S.), Endo International plc. (Ireland), Alvogen Group Inc. (U.S.), Sparsha Pharma International Pvt Ltd (India), Iontopatch (U.S.), Medherant Limited (U.K.), Luye Pharma Group (China), AbbVie Inc. (U.S.), Cipla Inc. (India), Teva Pharmaceutical Industries Ltd. (Israel), Agile Therapeutics (U.S.), Bayer AG (Germany), Amneal Pharmaceuticals LLC. (U.S.), Hikma Pharmaceuticals PLC (U.K.), AdhexPharma (France), Evernow (U.S.), LEAD CHEMICAL Co., Ltd. (Japan), Purdue Pharma L.P (U.S.) and Mundipharma International (U.K.)
The global glycated albumin assay market is projected to reach USD 0.3 billion by 2028 from USD 0.2 billion in 2023, at a CAGR of 8.9% during the forecast period. The increased number of diabetes cases is the major factor driving the glycated albumin assay market’s growth.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=265553363
The technologies that power glycated albumin assays are rapidly evolving to help overcome some challenges of utilizing these tests, including improving their clinical utility. The peroxidase method is an example that uses an immunological sandwich amplification and the enzyme peroxidase to affect a signal. This procedure is the enzyme-antibody solution, the PAP immune complex. It is exquisitely sensitive and has been used with high sensitivity and specificity.
The glycated albumin assay market is segmented based on application into prediabetes, type 1 diabetes, and type 2 diabetes. In 2022, the type 2 diabetes segment accounted for the largest glycated albumin assay market share. The significant growth of this segment is mainly attributed to the increased burden of type 2 diabetes worldwide, especially in the emerging countries in Asia Pacific, and increased government focus on the diagnosis of diabetes and ailments related to diabetes.
Based on end user, the glycated albumin assay market is segmented into hospitals and diabetes care centers, diagnostic laboratories,, and other end users. The hospital and diabetes care centers segment accounted for the largest glycated albumin assay market share in 2022. The increasing number of hospitals worldwide, owing to the growing burden of diseases & disorders, is a primary growth driver for this segment. Major economies are focusing on increasing the establishment of hospitals in their respective healthcare systems.
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa are the five main geographic segments of the worldwide glycated albumin assay market. The North American market is estimated to experience the highest share during the forecast period. The increasing population of elderly (65 years and above) and their age-related chronic diseases and improved focus on spreading awareness of the importance of early diagnosis and control of chronic diseases like diabetes can be credited for North America’s significant market share.
Asahi Kasei Corporation (Japan), Beijing Strong Biotechnologies, Inc. (China), Diazyme Laboratories, Inc. (US), DxGen Corp. (South Korea), Weldon Biotech, Inc. (India), Hymes Biotech (China) are some of the key players operating in this ecosystem.
Several countries in the Asia Pacific region have also implemented initiatives to promote the adoption of early diagnosis of diabetes and related diseases. For instance, countries such as India and Japan have launched precision diabetes diagnosis and control programs focusing on diabetes-related research and diabetes diagnosis and control in routine healthcare. Such factors are expected to support the region’s glycated albumin assay market growth.
Some key players in the glycated albumin assay market are Asahi Kasei Corporation (Japan), Beijing Strong Biotechnologies, Inc. (China), Diazyme Laboratories, Inc. (US), DxGen Corp. (South Korea), Weldon Biotech, Inc. (India), and Hzymes Biotech (China). The market leadership of these players stems from their comprehensive product portfolios. These dominant market players possess several advantages, including strong marketing and distribution networks, substantial research and development budgets, and well-established brand recognition.
The global softgel capsules market is projected to reach USD 1.5 billion by 2028 from USD 1.1 billion in 2023, at a CAGR of 6.3% during the forecast period. Factors such as advantages of softgel capsules, growing demand for nutraceuticals and dietary supplements, and growing demand for naturally sourced ingredients.However, restricted acceptance due to cultural restrictions is expected to hinder the growth of this market.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=238329912
On the basis of material type, the global softgel market is divided into gelatin, and other materials (such as carrageenan, hydroxypropyl methylcellulose (HPMC), pullulan, and starch-glycerin. In 2022, the gelatin segment accounted for the largest market share. Factors such as the advantages of soft gelatin capsules, such as no taste, unit dose delivery, easy to swallow, tamper-proof, and availability in a wide range of shapes, colors, and sizes, and growing demand for health supplements are supporting the growth of this market. In extension to this the growth of raw materials used for softgel capsules.
On the basis of source, the global softgel capsules market has been divided into porcine, bovine, and other sources (including poultry, marine, and plant sources). In 2022, bovine segment accounted for the largest share of softgel capsules market. Bovine softgels are known for their soft and flexible texture, which make them easy to swallow and digest and the abundance and easy availability of bovine are supporting its growth in the market. Strong emphasis on the launch of new products in the market specifically for softgels is further likely to have a positive impact on the market growth.
On the basis of application, the global softgel capsules market is divided into pharmaceutical, nutraceutical and dietary supplement, and cosmetics & personal care industries. In 2022, nutraceutical and dietary supplement industry segment accounted for the largest market share. Factors such as the icreasing consumer preference for capsule-based nutraceutical formulations is one of the major factors driving the growth of softgel capsules market for the nutraceutical industry. In addition, the growing demand for specialized dietary supplements is driving innovation in the softgel capsules market.
On the basis of region, the softgel capsules market has been segmented into, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, Europe accounted for the largest share of the softgel capsules market followed by North America. Factors such as changes in consumer lifestyles, growth in pharmaceutical industry and the presence of major capsule manufacturers and pharmaceutical giants in the region, such as Gelita AG (Germany), PB Leiner (Belgium), Weishardt SA (France), and Lapi Gelatine S.p.a. (Italy). This is expected to support the growth of softgel capsules market.
Key players in the softgel capsules market are Gelita AG (Germany), PB Leiner (part of Tessenderlo Group) (Belgium), Nitta Gelatin, Inc. (Japan), Sterling Gelatin and Croda Colloids (India), Narmada Gelatines Limited (India), Italgel S.r.l. (Italy), Darling Ingredients Inc. (US), Lapi Gelatine S.p.a. (Italy), Trobas Gelatine B.V. (Netherlands), Weishardt (France), India Gelatine & Chemicals Ltd. (India), Xiamen Gelken Gelatin Co., Ltd. (China), Gelco International (Brazil), Boom Gelatin (China), Geliko LLC (US), Kenney & Ross Limited Marine Gelatin (Canada), Baotou Dongbao Bio-Tech Co., Ltd. (China), Jellice Gelatin & Collagen (Netherlands), Athos Collagen Pvt. Ltd. (India), Kubon Biotechnology Co., Ltd. (Cambodia), C.J. Gelatine Products Limited (India), American Gelatin (US), and Geltech (South Korea).
Recent Developments of Softgel Capsules Industry
In March 2023, Darlings Ingredients Inc. acquired Gelnex, which is a global producer of gelatin and collagen products. This acquisition would give the company the capacity to serve the growing needs of its collagen customers while continuing to serve the growing gelatin market.Thermo fisher launched Tumoroid Culture Medium to accelerate development of novel cancer therapies.
In November 2022, PB Leiner established a joint venture with D&D Participações Societárias. Under the terms of this joint venture, D&D Participações Societárias will acquire a minority stake in the shares of the Brazilian plant of PB Leiner (PB Brasil Industria e Comercio de Gelatinas Ltda). The combined strength of the two companies will enable a long-term sustainable offering of a premium product range of beef hide gelatin based on PB Leiner’s technology.
In October 2022, PB Leiner extended the gelwoRx Dsolve pharmaceutical portfolio with the launch of three new products—Dsolve B, Dsolve P, and Dsolve xTRA. Dsolve P (pig skin) and Dsolve B (beef hide) are specially developed to reduce cross-linking and fast dissolution of soft capsules. Dsolve xTRA (bovine bone) promises to perform better than Dsolve, Dsolve P, and Dsolve B.
The single-use bioprocessing market is expected to grow at a CAGR of 14.5% during the forecast period. The market is estimated to be around USD 17.7 billion in 2024 and is projected to reach USD 34.9 billion by 2029. Growing biologics & biosimilars market, need for low capital investment, a surge in single-use bioprocessing adoption among CDMOs & CMOs, and advantages such as increased productivity & reduced risk of cross contamination, are some factors responsible for the growth of the market. On the other hand, issues related to leachables & extractables, regulatory compliance, and discussions about PFAS restrictions are hampering the market growth.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231651297
Based on products, the single-use bioprocessing market is segmented into equipment and consumables. The consumables segment accounted for the largest share and is also estimated to grow at the highest CAGR of the single-use bioprocessing market. This can be attributed to their repeated purchase, higher usage, frequent replacement, and broad application range.
Based on application, the single-use bioprocessing market is segmented into cell culture, filtration, purification, mixing, storage & transfer, and other applications. The filtration segment accounted for the largest share of the single-use bioprocessing market. The large share of this segment can be attributed to the wide use of equipment for various filtration applications in the pharmaceutical industry, increased filtration requirements in the biopharmaceutical industry, and the higher requirement for these filters compared to consumables and filtration accessories.
Based on workflow, the single-use bioprocessing market is segmented into upstream and downstream bioprocessing. The growth of the single-use bioprocessing market for upstream bioprocesses is driven by technological advancements and strategic collaborations between industry players. For instance, in June 2023, Culture Biosciences and Cytiva collaborated to introduce new bioprocess solutions that leverage digitization, in-silico approaches, and virtual monitoring and control of experiments. This collaboration revolutionized upstream processing by providing customers unprecedented access to cutting-edge technologies and methodologies, fueling the demand for advanced bioprocessing solutions.
Based on molecule type, the single-use bioprocessing market is segmented into monoclonal antibodies (mAbs), vaccines, therapeutic proteins & peptides, and cell & gene therapies. mAbs accounted for the largest share of the single-use bioprocessing market. The large share is attributed to the increasing pharmaceutical R&D drug pipeline, increasing incidence of cancer, and rising usage & demand for cancer therapy.
Based on the end user, the single-use bioprocessing market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and CMOs & CROs. In 2023, pharmaceutical & biotechnology companies accounted for the largest share of the single-use bioprocessing market due to their higher adoption of single-use bioprocessing equipment and consumables, the stringent regulatory scenario, increased R&D activities, increased production of biologics, and rising manufacturing of biologics and biosimilars in developed countries.
Based on region, single-use bioprocessing market is segmented into six major regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the single-use bioprocessing market. Europe held the second largest share followed by the Asia Pacific. The Asia Pacific market is expected to show the highest growth rate during the forecast period. Growing pharmaceutical R&D activities, increasing demand for biosimilars, significant investments by biopharmaceutical companies & CMOs in emerging Asia Pacific countries, are some of the factors contributing to the regional growth.
Key players in the single-use bioprocessing market include Sartorius AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Avantor, Inc. (US), 3M Company (US), Repligen Corporation (US), Entegris (US), Getinge AB (Sweden), Parker Hannifin Corporation (US), Alfa Laval Corporate AB (Sweden), Saint-Gobain (France), Eppendorf SE (Germany), Corning Incorporated (US), Eaton Corporation plc (Ireland)v, METTLER TOLEDO (US), Porvair PLC (UK), Lonza (Switzerland), ABEC, INC. (US), NewAge Industries (US), PBS Biotech, Inc. (US), Sentinel Process Systems, Inc. (US), Meissner Filtration Products, Inc. (US), SATAKE MultiMix Corporation (Japan), Hamilton Company (US), Membrane Solutions (US), Cole-Parmer Instrument Company, LLC (US), Distek, Inc. (US), Esco Lifesciences Group Ltd. (US), and TECNIC Bioprocess solutions (Spain).
Recent Developments of the Single Use Bioprocessing Industry:
In April 2024, Cytiva introduced the Xcellerex magnetic mixer, a single-use mixing system in 2,000 and 3,000 L capacities for large-scale mAb, vaccine, and genomic medicine manufacturing processes.
In April 2023, Merck KGaA launched the Ultimus single-use process container film designed to provide extreme durability and leak resistance for single-use assemblies used for bioprocessing liquid applications.
The global adhesion barrier market size is projected to reach USD 0.9 billion by 2028 from USD 0.7 billion in 2023, at a CAGR of 7.4%. The main drivers driving the growth of this market are the increasing amount of surgeries and sports-related injuries, a growing elderly population, and increasing understanding of adhesion formation and conditions associated with adhesions. During the forecast period, this market’s growth is anticipated to be constrained by surgeons’ resistance to using adhesion barriers.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=208132543
Based on products, the adhesion barriers market is further segmented into synthetic and natural adhesion barriers. In 2022, the synthetic adhesion barriers segment accounted for the largest share of the adhesion barriers market. The large number of synthetic adhesion barriers that are commercially available and their higher utilisation by surgeons in various surgical procedures as compared to natural adhesion barriers can be attributed to the segment’s growth. The sub-segment of synthetic adhesion barriers includes hyaluronic acid, regenerated cellulose, polyethylene glycol, and other synthetic adhesion barriers. Because they are biocompatible and bioresorbable, hyaluronic acid-based adhesion barriers have the largest market share in the synthetic adhesion barrier market. These are frequently used for open and laparoscopic general surgeries, including those involving the abdomen, pelvis, gynaecology, and other surgeries.
Based on the type of formulation, the adhesion barriers market is segmented into film formulations, gel formulations, and liquid formulations. Given surgeon’s increased preference for adhesion barriers in the form of films as well as the availability of clinical safety and efficacy data for these formulations, film formulations dominated the adhesion barrier market in 2022.
Based on applications, General/Abdominal Surgeries surgeries held the largest share of the adhesion barriers market in 2022. A number of factors, including the increased risk of post-surgical adhesion formation in general/abdominal surgeries, the rising number of general/abdominal surgeries, and the availability of several commercialized adhesion barrier products for general/abdominal surgeries, can be attributed to the general/abdominal surgeries segment the large share of this market
Based on end user, hospitals and clinics held the largest share of the adhesion barriers market in 2022. The largest share of this segment in the market of adhesion barrier is attributed to the large number of surgeries happening in the hospitals and clinics in both developed and developing countries.
Geographically, the adhesion barriers market is segmented into North America, Europe, Asia Pacific, Latin America, and The Middle East and Africa. The North America’s strong healthcare system, higher public and private expenditures on health care, growing numbers of the geriatric population, and an increasing prevalence of chronic and lifestyle diseases all contributed to North America having the largest share of the adhesion barrier market. On the other hand, the APAC market for adhesion barrier will expand due to factors like the rapidly growing geriatric population, the epidemiological shift from infectious to chronic diseases, and the rise in medical tourism. As a result, the APAC is anticipated to grow at a higher CAGR than other regions during the forecast period.